Description of invariant NKT cells
DOI:
https://doi.org/10.12775/JEHS.2021.11.09.053Keywords
tumor microenvironment, invariant natural killer T cells, iNKT, tumor, immunology, cytokinesAbstract
Recently discovered subpopulations belonging to cell groups called “invariant” NKT, also referred to as type I NKT or classical NKT cells, appear to have a unique impact on the tumor microenvironment. Considering the characteristics of secreted cytokines, production of chemokines and the capability of cell cytotoxic activity, these cells have a significant function in being immune to bacteria, parasites, viruses, autoimmune and tumor diseases. The profile of secreted cytokine is probably decisive in reference to the distinct functions of the subpopulation, some of them exhibit immunosuppressive activity inhibiting an anticancer immune response, and the other stimulate the organisms for eradicating the tumor. Currently, it has been discovered six fundamental, functionally distinct subpopulations of iNKT cells (NKT1, NKT2, NKT10, NKT17, NKTreg, NKTFH).
References
Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, Gong Z, Zhang S, Zhou J, Cao K, Li X, Xiong W, Li G, Zeng Z, Guo C. Role of tumor microenvironment in tumorigenesis. J Cancer. 2017 Feb 25;8(5):761-773. doi: 10.7150/jca.17648. PMID: 28382138; PMCID: PMC5381164.
Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012 Dec 1;125(Pt 23):5591-6. doi: 10.1242/jcs.116392. PMID: 23420197.
Sounni NE, Noel A. Targeting the tumor microenvironment for cancer therapy. Clin Chem. 2013 Jan;59(1):85-93. doi: 10.1373/clinchem.2012.185363. Epub 2012 Nov 28. PMID: 23193058.
Mussai F, De Santo C, Cerundolo V. Interaction between invariant NKT cells and myeloid-derived suppressor cells in cancer patients: evidence and therapeutic opportunities. J Immunother. 2012 Jul;35(6):449-59. doi: 10.1097/CJI.0b013e31825be926. PMID: 22735803.
McEwen-Smith RM, Salio M, Cerundolo V. The regulatory role of invariant NKT cells in tumor immunity. Cancer Immunol Res. 2015 May;3(5):425-35. doi: 10.1158/2326-6066.CIR-15-0062. PMID: 25941354; PMCID: PMC4430818.
Rossjohn J, Pellicci DG, Patel O, Gapin L, Godfrey DI. Recognition of CD1d-restricted antigens by natural killer T cells. Nat Rev Immunol. 2012 Dec;12(12):845-57. doi: 10.1038/nri3328. Epub 2012 Nov 16. PMID: 23154222; PMCID: PMC3740582.
Favreau M, Vanderkerken K, Elewaut D, Venken K, Menu E. Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma? Oncotarget. 2016 Apr 26;7(17):23128-40. doi: 10.18632/oncotarget.7440. PMID: 26895468; PMCID: PMC5029615.
Carreño LJ, Kharkwal SS, Porcelli SA. Optimizing NKT cell ligands as vaccine adjuvants. Immunotherapy. 2014;6(3):309-20. doi: 10.2217/imt.13.175. PMID: 24762075; PMCID: PMC4128316.
Terabe M, Berzofsky JA. The role of NKT cells in tumor immunity. Adv Cancer Res. 2008;101:277-348. doi: 10.1016/S0065-230X(08)00408-9. PMID: 19055947; PMCID: PMC2693255.
Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol. 2004 Mar;4(3):231-7. doi: 10.1038/nri1309. PMID: 15039760.
Buechel HM, Stradner MH, D'Cruz LM. Stages versus subsets: Invariant Natural Killer T cell lineage differentiation. Cytokine. 2015 Apr;72(2):204-9. doi: 10.1016/j.cyto.2014.12.005. Epub 2015 Jan 31. PMID: 25648290; PMCID: PMC4864435.
Wallace ME, Alcantara MB, Minoda Y, Kannourakis G, Berzins SP. An emerging role for immune regulatory subsets in chronic lymphocytic leukaemia. Int Immunopharmacol. 2015 Oct;28(2):897-900. doi: 10.1016/j.intimp.2015.03.047. Epub 2015 Apr 7. PMID: 25862133.
Matsuda JL, Mallevaey T, Scott-Browne J, Gapin L. CD1d-restricted iNKT cells, the 'Swiss-Army knife' of the immune system. Curr Opin Immunol. 2008 Jun;20(3):358-68. doi: 10.1016/j.coi.2008.03.018. Epub 2008 May 22. PMID: 18501573; PMCID: PMC2546701.
Robertson FC, Berzofsky JA, Terabe M. NKT cell networks in the regulation of tumor immunity. Front Immunol. 2014 Oct 28;5:543. doi: 10.3389/fimmu.2014.00543. PMID: 25389427; PMCID: PMC4211539.
Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol. 2007;25:297-336. doi: 10.1146/annurev.immunol.25.022106.141711. PMID: 17150027.
Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today. 2000 Nov;21(11):573-83. doi: 10.1016/s0167-5699(00)01735-7. PMID: 11094262.
Kaszubowska L, Piotrowska A, Siedlecka-Kroplewska K, Kmieć Z. Komórki NKT jako element łączący odporność wrodzoną z odpornością nabytą. [NKT cells as a connecting element between innate and adaptive immunity.] Post. Biol. Kom. 2013; t. 40, nr 4, p. 697-724.
Hung JT, Huang JR, Yu AL. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses. J Biomed Sci. 2017 Mar 23;24(1):22. doi: 10.1186/s12929-017-0325-0. PMID: 28335781; PMCID: PMC5364570.
Fallarini S, Paoletti T, Orsi Battaglini N, Lombardi G. Invariant NKT cells increase drug-induced osteosarcoma cell death. Br J Pharmacol. 2012 Dec;167(7):1533-49. doi: 10.1111/j.1476-5381.2012.02108.x. PMID: 22817659; PMCID: PMC3514765.
Hix LM, Shi YH, Brutkiewicz RR, Stein PL, Wang CR, Zhang M. CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis. PLoS One. 2011;6(6):e20702. doi: 10.1371/journal.pone.0020702. Epub 2011 Jun 13. PMID: 21695190; PMCID: PMC3113806.
De Santo C, Arscott R, Booth S, Karydis I, Jones M, Asher R, Salio M, Middleton M, Cerundolo V. Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. Nat Immunol. 2010 Nov;11(11):1039-46. doi: 10.1038/ni.1942. Epub 2010 Oct 3. PMID: 20890286; PMCID: PMC3001335.
Gapin L. Development of invariant natural killer T cells. Curr Opin Immunol. 2016 Apr;39:68-74. doi: 10.1016/j.coi.2016.01.001. Epub 2016 Jan 21. PMID: 26802287; PMCID: PMC4801673.
Bricard G, Cesson V, Devevre E, Bouzourene H, Barbey C, Rufer N, Im JS, Alves PM, Martinet O, Halkic N, Cerottini JC, Romero P, Porcelli SA, Macdonald HR, Speiser DE. Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors. J Immunol. 2009 Apr 15;182(8):5140-51. doi: 10.4049/jimmunol.0711086. PMID: 19342695.
Wolf BJ, Choi JE, Exley MA. Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy. Front Immunol. 2018 Mar 2;9:384. doi: 10.3389/fimmu.2018.00384. PMID: 29559971; PMCID: PMC5845557.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 © The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 435
Number of citations: 0
